Skip to content

Author

S. Fähndrich

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Safety and pharmacokinetics of inhaled aloxistatin: A first-in-human phase 1 dose escalation trial.

AIMS Aloxistatin (E64d) is a membrane-permeable cysteine protease inhibitor prodrug that is converted by esterases to the active metabolite E64c (loxistatin). This first-in-human study evaluated the safety, tolerability and pharmacokinetics of single ascending doses of inhaled E64d in healthy volunteers. METHODS In t...

S. Fähndrich, Franziska Friedrich, Daniel Soriano et al. · 0 citations
Review Open access Sep 2026

Control first, tolerance second: biologics as enablers of allergen immunotherapy in severe allergic asthma

It is concluded that biologic-enabled AIT is a promising but insufficiently defined strategy, and the prospective trials, standardized phenotyping, and safety registries needed to establish it as an evidence-based clinical pathway are outlined.

B. Jentzsch, A. Hoheisel, K. Gashynova et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.